Keytruda biosims are coming — but they face an uphill battle
The FDA accepted an application for FYB206, a biosimilar to Merck & Co.'s Keytruda, with a potential approval by Q3 2027. Keytruda generated $31.7 billion in 2025. Biosimilars face market challenges due to deals favoring branded drugs, despite FDA support. Formycon and Zydus Lifesciences aim to commercialize FYB206 in the U.S. and Canada, with regulatory pathways that may reduce development costs.
How this was made
The 30-second read
Why it matters
Regulatory progress (FDA acceptance and a development pathway that avoids comparative phase 3 efficacy) could accelerate biosimilar development, but market adoption may be constrained by PBM and payer incentives that favor branded products.
Market read
Traders in oncology biologics and biosimilars should monitor FYB206’s regulatory trajectory and the indication scope, since both determine how much Keytruda revenue is exposed.
What to watch
The article notes uncertainty around which Keytruda indications FYB206 could cover due to orphan exclusivity and potential infringement disputes, which could reduce the competitive footprint.
Background
The FDA accepted the first publicly announced Keytruda biosimilar application (FYB206), with potential approval as early as 3Q 2027, as Keytruda approaches patent expirations beginning in 2028.
Ticker impact
The article says Keytruda generated $31.7B for Merck in 2025 and faces a patent cliff starting in 2028, raising competitive risk from biosimilars.
Likely downward pressure as investors price earlier-than-expected competitive erosion of Keytruda revenues.
The piece links FDA acceptance of FYB206 to potential approval timing and frames it as competition for Keytruda, Merck’s blockbuster, with additional market adoption hurdles.
Market effects
Highlights biosimilar adoption friction (PBM incentives, formularies) that can limit uptake even after regulatory approvals, affecting the broader biosimilars trade.
US FDA pathway and US/Canada commercialization plans make the US market the primary battleground for competitive dynamics.
If the FYB206 development pathway sets a precedent, it could influence biosimilar regulatory strategies beyond the US over time.
Counterpoint
Even with an FDA nod, biosimilar uptake may remain muted if PBMs continue prioritizing high-rebate branded biologics, limiting near-term revenue impact.
Key entities
- companyMerck & Co.
Keytruda’s manufacturer; the article cites $31.7B Keytruda revenue in 2025 and frames patent-cliff risk from incoming biosimilars.
- companyFormycon
Developer of FYB206; the article says FDA agreed on a development pathway without comparative phase 3 efficacy.
- companyZydus Lifesciences
Partner tapped to commercialize FYB206 in the US and Canada.
- regulatorFDA
Accepted FYB206 application and has a Biosimilars Action Plan intended to support development and market adoption.
